Literature DB >> 19658058

Selective deficiency of Gsalpha and the possible role of alternative gene products of GNAS in Albright hereditary osteodystrophy and pseudohypoparathyroidism type Ia.

S Thiele1, R Werner, W Ahrens, A Hübner, K G Hinkel, W Höppner, B Igl, O Hiort.   

Abstract

OBJECTIVE: Albright hereditary osteodystrophy (AHO) and Pseudohypoparathyroidism type Ia (PHPIa) are caused by an inherited deficiency of Gsalpha, encoded by the GNAS gene. Apart from an exclusive first exon, Gsalpha shares part of the transcribed regions with NESP55, Exon A/B and XLalphas, whose gene products utilize alternative promoter regions of this complex gene locus. However, it is not known, whether the deficiency of all gene products contributes to the AHO and PHPIa phenotype or if they are even causative for some specific symptoms. In these cases, mutations affecting selectively GNAS exon 1, coding only for Gsalpha, would lead to a different phenotype than mutations affecting the common exons 2-13.
METHODS: Clinical and molecular genetic analysis of a patient with features of AHO and review of exclusive exon 1 mutations of GNAS.
RESULTS: We detected a novel heterozygous 1 bp deletion of a guanine in codon 31 in exon 1 of the GNAS gene leading to a frame shift and premature termination of Gsalpha. The female patient demonstrated a fully expressed AHO and PHPIa phenotype and a decreased Gsalpha protein activity of 62% compared to the wild type. Mutations in exon 1 are almost exclusively disruptive and lead to an AHO phenotype that does not show obvious differences from those provoked by missense or nonsense mutations in exon 2-13.
CONCLUSION: Disruptive mutations in exon 1 indicate that exclusive deficiency of Gsalpha is sufficient for the expression of an AHO phenotype, which cannot be compensated by alternative products of GNAS. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart. New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19658058     DOI: 10.1055/s-0029-1215589

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

Review 1.  A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature.

Authors:  Alessandro Brancatella; Giovanna Mantovani; Francesca M Elli; Simona Borsari; Claudio Marcocci; Filomena Cetani
Journal:  Endocrine       Date:  2020-01-14       Impact factor: 3.633

2.  Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature.

Authors:  Yun-Ling Li; Ting Han; Fang Hong
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

Review 3.  GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders.

Authors:  Manuel C Lemos; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2014-11-28       Impact factor: 4.878

4.  A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.

Authors:  Susanne Thiele; Ralf Werner; Joachim Grötzinger; Bettina Brix; Pia Staedt; Dagmar Struve; Benedikt Reiz; Jennane Farida; Olaf Hiort
Journal:  Mol Genet Genomic Med       Date:  2014-12-04       Impact factor: 2.183

Review 5.  Progressive osseous heteroplasia: diagnosis, treatment, and prognosis.

Authors:  Robert J Pignolo; Girish Ramaswamy; John T Fong; Eileen M Shore; Frederick S Kaplan
Journal:  Appl Clin Genet       Date:  2015-01-30

Review 6.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.